<DOC>
	<DOCNO>NCT02092116</DOCNO>
	<brief_summary>The REDUC trial 's objective address one core issue treatment HIV , HIV infect cell hide so-called latent reservoir . The reservoir unaffected conventional HIV medication invisible immune system . HDACi potential activate latently infected cell . This make HIV infect cell visible immune system ; immune response generate Vacc-4x able attack eliminate infect cell .</brief_summary>
	<brief_title>Safety Efficacy Romidepsin Therapeutic Vaccine Vacc-4x Reduction Latent HIV‐1 Reservoir</brief_title>
	<detailed_description>The study divide two part . In Part A safety tolerability romidepsin evaluate effect romidepsin treatment HIV-1 transcription HIV-infected patient virologically suppress cART determine . In Part B effect treatment Vacc-4x + rhuGM-CSF romidepsin treatment HIV-1 latent reservoir HIV-infected patient virologically suppress cART measure . Six patient enrolled part A safety tolerability profile evaluate enrol 20 patient B .</detailed_description>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Currently receive cART receive cART minimum 1 year 3 . HIV1 plasma RNA &lt; 50 copies/mL least 1 year ( exclude viral load blip ) 4 . CD4 T cell count ≥500 cells/mm3 1 . CD4 T cell count nadir &lt; 200 cells/mm3 2 . Previous treatment HDACi ( Histone deacetylase inhibitor ) within previous 6 month 3 . Any evidence active AIDSdefining opportunistic infection , active HBV HCV coinfection , significant cardiac disease , malignancy , transplantation , insulin dependent diabetes mellitus protocol define excluded medical condition 4 . Use protocol define contraindicated medication vaccination 5 . Unacceptable value hematologic clinical chemistry parameter define protocol . 6 . Males females unwilling unable use protocol define method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>